<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914771</url>
  </required_header>
  <id_info>
    <org_study_id>V87_17</org_study_id>
    <nct_id>NCT00914771</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects</brief_title>
  <official_title>A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study aims to demonstrate the non-inferiority of two doses of H5N1 influenza antigen in
      non-elderly and elderly adult subjects in order to submit an extension application for a
      lower dose of Focetria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 43 post vaccination ratio of GMTs for the 2 different vaccine groups (3.75µ / 7.5µg) including two-sided 95% confidence intervals as measured by HI and SRH in the adult and elderly population combined.</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited local reactions: ecchymosis, erythema, induration, swelling and pain at injection site.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited systemic reactions: headache, arthralgia, chills, fatigue, malaise, myalgia, nausea, sweating and fever as measured by axillary temperature for Day 1 through 7 and Day 22 to 28 of the study.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers/area (GMTs/GMAs) on each blood sampling days as determined by HI and SRH, and the applicable geometric mean ratios.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion or significant increase in antibody titer on each post-vaccination blood sampling days, as measured by HI and SRH.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving an HI titer ≥40/ SRH area ≥25mm² on each blood sampling days.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, as determined by HI or SRH, will be assessed according to age-appropriate CHMP criteria (CPMP/BWP/214/96).</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity according to CBER criteria in terms of hemagglutination inhibition test in non-elderly adult and elderly subjects separately, for all post-vaccination blood sampling days and the immunogenicity according to microneutralization test</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">722</enrollment>
  <condition>Pandemic H5N1 Influenza</condition>
  <arm_group>
    <arm_group_label>H5N1 pandemic Influenza vaccine 3.75µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 pandemic Influenza vaccine 7.5µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H5N1 pandemic Influenza vaccine 3.75µg</intervention_name>
    <description>2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen</description>
    <arm_group_label>H5N1 pandemic Influenza vaccine 3.75µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H5N1 pandemic Influenza vaccine 7.5µg</intervention_name>
    <description>2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen</description>
    <arm_group_label>H5N1 pandemic Influenza vaccine 7.5µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 yrs of age and above on the day of enrollment.

          -  Individuals in good health as determined by medical history, physical examination and
             clinical judgment of the investigator

          -  Documented consent obtained after the nature of the study has been explained according
             to local regulatory requirements

          -  Individuals are able to comply with all study procedures and are available for all
             clinic visits scheduled in the study

        Exclusion Criteria:

          -  Individuals who are not able to comprehend and to follow all required study procedures
             for the whole period of the study or who do not consent to the retention of the
             subject's serum samples after study completion.

          -  Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, may interfere with the subject's ability to
             participate in the study

          -  Individuals with history or any illness that, in the opinion of the investigator,
             might interfere with the results of the study or pose additional risk to the subjects
             due to participation in the study

          -  Individuals who have had influenza vaccine or documented suspected influenza disease
             within 6 months prior to Day 1.

        Laboratory-confirmed or suspected influenza disease within 6 months prior to Visit 1.
        &quot;Laboratory-confirmed&quot; includes:

          1. Positive serology result

          2. Positive viral culture

          3. Positive rapid antigen test

          4. &quot;Suspected&quot; influenza disease includes: subjects with influenza-like illness within
             the past 6 months with a household/intimate contact with &quot;laboratory-confirmed&quot;
             influenza disease

               -  Individuals experiencing any acute disease or infection requiring systemic
                  antibiotic or antiviral therapy within 6 days before vaccination (chronic
                  antibiotic therapy for urinary tract prophylaxis is acceptable)

               -  History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to
                  influenza viral proteins, to any excipients, and to eggs (including ovalbumin),
                  chicken protein.

               -  History of any serious disease, such as:

        a. Medically significant cancer (except for benign or localized skin cancer, cancer in
        remission for ≥10 years or localized prostate cancer that has been clinically stable for
        more than 2 years without treatment) b. autoimmune disease (including rheumatoid arthritis)
        except for Hashimoto's thyroiditis that has been clinically stable for ≥ 5 years; c.
        diabetes mellitus type I; d. poorly controlled diabetes mellitus type II; e. diabetes
        relating to genetic defects/syndromes, diseases of the exocrine pancreas, or infections; f.
        advanced arteriosclerotic disease; g. severe chronic obstructive pulmonary disease (COPD),
        i.e. GOLD stages 3 and 4; h. acute or progressive hepatic disease; i. acute or progressive
        renal disease; j. medically significant congestive heart failure; k. history of underlying
        medical condition such as major congenital abnormalities requiring surgery, chronic
        treatment, or associated with developmental delay (e.g., Down's syndrome)

          -  Known or suspected impairment/alteration of immune function, including:

               1. Receipt of immunosuppressive therapy such as oral or systemic corticosteroids,
                  (use of inhaled, intranasal, or topical corticosteroids is allowed) or cancer
                  chemotherapy within 60 days prior to Visit 1

               2. receipt of immunostimulants within 60 days prior to Visit 1

               3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivates within 3 months prior to Visit 1 or planned during the full length of
                  the study

               4. HIV infection or HIV-related disease

               5. Heritable immunodeficiency

               6. Abnormalities of splenic or thymic function

          -  Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for
             live vaccines) prior to Day 1 or planned vaccination before Day 43. Seasonal influenza
             vaccination is allowed 3 weeks after last study vaccination (after the blood sampling
             for serology on Day 43)

          -  Experienced body temperature ≥38.0°C (100.4°F) within 3 days prior to each study
             vaccination.

          -  Use of antipyretic/analgesic medication within 24 hours of each study vaccination

          -  Receipt of another investigational agent within 30 days prior to enrollment in the
             study or before completion of the safety follow-up period in another study, whichever
             is longer, prior to enrollment and unwilling to refuse participation in another
             clinical study through the end of the study

          -  Pregnant or breast-feeding female

          -  Any positive or indeterminate pregnancy test

          -  If female, of childbearing potential, and has not used any of the &quot;acceptable
             contraceptive methods&quot; for at least 2 months prior to study entry

               1. Of childbearing potential is defined as status post onset of menarche and not
                  surgically sterile

               2. Acceptable birth control methods are defined as one or more of the following:

             i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant,
             cervical ring) ii. Barrier (condom with spermicide or diaphragm with spermicide) each
             and every time during intercourse iii. Intrauterine device (IUD) iv. Monogamous
             relationship with vasectomized partner. Partner must have been vasectomized for at
             least six months prior to the subject's study entry

          -  If female of childbearing potential, refusal to use an &quot;acceptable contraceptive
             method&quot; during the study including day 43.

          -  If female of childbearing potential, refusal to submit for pregnancy testing prior to
             study vaccination

          -  Research staff directly involved with the clinical study or family members or
             household members of research staff. Research staff are individuals with direct or
             indirect contact with study subjects, or study site personnel who have access to any
             study documents containing subject information. This would include receptionists,
             persons scheduling appointments or making screening calls, regulatory specialists,
             laboratory technicians, etc.

          -  Elective surgery or hospitalization planned during the period of study participation.

          -  BMI &gt;35Kg/m2 where BMI is for obese and not for high muscle mass

          -  Individuals with history of substance or alcohol abuse within the past 2 years that in
             the opinion of the Investigator might interfere with the safety of the subject or the
             evaluation of the study objectives.

          -  Any condition, which in the opinion of the Investigator, might interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NZOZ Centrum Zdrowia &quot;Blonie&quot;</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prakytka Lekarzy Rodzinnych &quot;Salus&quot;</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Internistyczny</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital Dzieciecy im.</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodyielny Publiczny ZOZ</name>
      <address>
        <city>Lubartow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Praktyka Lekarza Rodzinnego &quot;Eskulap&quot;</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi Universitesi Tip Fakultesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Ic Hastaliklan</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C.S.B. Ankara Numune Egitim ve Arastirma</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C.S.B.Ataturk Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osmangazi Universitesi Tip Fakutesi</name>
      <address>
        <city>Eskisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enfeksiyon Hastaliklari ve Klinik Mikeoviyloji</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pandemic Influenza</keyword>
  <keyword>H5N1</keyword>
  <keyword>Adults and Elderly</keyword>
  <keyword>antigen dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

